Advances in cell therapies for Parkinson's, GLP-1 agonists and dementia risk, FDA accelerated approvals for neurology drugs
Neurology Today in 5Show Notes
In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles about early studies finding dopamine cellular therapies were safe and tolerable for patients with Parkinson's, use of GLP-1 agonists were associated with reduced dementia risks, and the FDA use of accelerated approvals for several neurology drugs are under scrutiny.
More from Neurology Today in 5
In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about the use of lamotrigine during pregnancy, the value of professional mentorship, and the misdiagnosis of CADASIL as multiple sclerosis.
In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about the pros and cons of wearable devices, new data for thrombectomy use in medium-vessel occlusion strokes, and a new treatment for limb-girdle muscular dystrophy type 2I/R9.
In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about the first oral PCSK9 inhibitor, the transforming role of the neurology department chair, and anti-IgLON5 disease.
In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles about new migraine prevention guidelines, the use of plasmapheresis for acute MOGAD attacks, and how sabbaticals can help neurologists avoid burnout.
In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles about the impact of the "One Big Beautiful Bill Act" on neurology practice and research, how artificial intelligence is transforming the neurologist's workload, and the relationship between GBA1 mutations and Parkinson's disease.